Maravai LifeSciences Holdings, Inc. (MRVI)
Stock Price:
$29.16 USD
2.20 (8.16%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $28.95 -0.21 (-0.72%) Nov 27, 4:53 PM
Key Info
| Market Cap |
7.74B |
| Revenue (ttm) |
221.71M |
| Net Income (ttm) |
58.37M |
| Shares Out |
267.84M |
| EPS (ttm) |
0.22 |
| PE Ratio |
132.55 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$29.16 |
| Previous Close |
$26.96 |
| Change ($) |
2.20 |
| Change (%) |
8.16% |
| Day's Open |
27.41 |
| Day's Range |
27.41 - 30.27 |
| Day's Volume |
5,155,393 |
| 52-Week Range |
25.56 - 32.46 |
More Stats
| Market Cap |
7.74B |
| Enterprise Value |
8.02B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
267.84M |
| Float |
59.93M |
| EPS (basic) |
n/a |
| EPS (diluted) |
0.22 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.75% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
132.55 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
34.91 |
| PB Ratio |
65.57 |
| Revenue |
221.71M |
| Operating Income |
n/a |
| Net Income |
58.37M |
| Free Cash Flow |
n/a |
| Net Cash |
-283.26M |
| Net Cash / Share |
-1.07 |
| Gross Margin |
53.30% |
| Operating Margin |
n/a |
| Profit Margin |
26.33% |
| FCF Margin |
n/a |
| ROA |
2.72% |
| ROE |
-3.55% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 143 | 124 |
| Revenue Growth | 15.59% | - |
| Gross Profit | 76.29 | 63.07 |
| Operating Income | 24.31 | 17.38 |
| Net Income | -4.47 | -4.47 |
| Shares Outstanding | 1,000 | 1,000 |
| Earnings Per Share | -8,481.00 | -17,727.00 |
| Operating Cash Flow | 24.12 | -0.19 |
| Capital Expenditures | -17.15 | -3.61 |
| Free Cash Flow | 6.97 | -3.80 |
| Cash & Equivalents | 24.70 | 21.87 |
| Total Debt | 390 | 340 |
| Net Cash / Debt | -366 | -318 |
| Assets | 578 | 540 |
| Liabilities | 433 | 392 |
| Book Value | 141 | 144 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Maravai LifeSciences Holdings, Inc. |
| Country |
United States |
| Employees |
390 |
| CEO |
Carl W. Hull |
Stock Information
| Ticker Symbol |
MRVI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MRVI |
| IPO Date |
November 20, 2020 |
Description
Maravai LifeSciences Holdings operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry. The company serves biopharmaceutical companies, and other emerging biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.